| Literature DB >> 31920356 |
Awad Alshahrani1,2,3, Mohammed AlDubayee1,2,3, Mahmoud Zahra3, Firas M Alsebayel3, Nawaf Alammari3, Faisal Alsudairy3, Muath Almajed3, Ahmad Aljada4.
Abstract
BACKGROUND: Interactions between environmental factors, such as diet and lifestyle, and metabolic pathways are pivotal in understanding aging mechanisms. hNAA40, Nicotinamide phosphoribosyltransferase (NAMPT), and NAD-dependent protein deacetylase sirtuin-1 (SIRT-1) have been shown to exert important biological processes, including stress response and aging.Entities:
Keywords: NAMPT; T2DM; hNAA40; nicotinamide phosphoribosyltransferase; obesity; senescence; sirtuin-1
Year: 2019 PMID: 31920356 PMCID: PMC6938199 DOI: 10.2147/DMSO.S228591
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Demographic Data of the Subjected Participated in the Study. Results are Presented as Mean ± S.E.M
| Group | Gender | Age (Years) | BMI kg/m2 | Glucose (mmol/L) | HbA1c (%) | Insulin (µU/mL) | LDL (mmol/L) | HDL (mmol/L) | Triglycerides (mmol/L) |
|---|---|---|---|---|---|---|---|---|---|
| Lean | 18M, 12F | 25.7 ± 1.1 | 23.0 ± 0.3 | 5.1 ± 0.1 | 5.8 ± 0.10 | 4.8 ± 0.60 | 2.54 ± 0.26 | 1.35 ± 0.04 | 0.83 ± 0.09 |
| Obese | 11M, 19F | 35.1 ± 2.3 | 39.1 ± 1.7* | 5.4 ± 0.1 | 5.6 ± 0.25 | 10.0 ± 1.5* | 3.04 ± 0.16 | 1.18 ± 0.05 | 1.22 ± 0.12 |
| T2DM | 15M, 5F | 48.4 ± 3.0*σ | 32.5 ± 1.9* | 10.0 ± 1.1*σ | 8.0 ± 0.62*σ | 7.5 ± 2.6* | 3.53 ± 0.19* | 1.02 ± 0.05*δ | 1.97 ± 0.23*δ |
| T2DM + Metformin | 12M, 18F | 47.1 ± 2.0*σ | 40.5 ± 1.5* | 10.0 ± 0.8*σ | 8.7 ± 0.35*σ | 7.8 ± 1.5* | 2.60 ± 0.17σ | 0.99 ± 0.04*δ | 1.56 ± 0.16* |
Notes: *P<0.05 vs lean subjects; σP<0.05 vs obese; δP<0.05 vs T2DM.
Primer Sequences for All Primers Used in RT-qPCR
| Primer | Sense (5’→3’) | Anti Sense (5’→3’) | Accession Number |
|---|---|---|---|
| hNAA40 | ACATCCATCTTTCTCCACTTCC | TCCCAAAGTGCTGGGATTAC | NM_024771.3 |
| NAMPT | CGGCAGAAGCCGAGTTCAA | GCTTGTGTTGGGTGGATATTGTT | NM_005746.3 |
| SIRT-1 | GCAGATTAGTAGGCGGCTTG | TCTGGCATGTCCCACTATCA | NM_012238.5 |
| GAPDH | TGCACCACCAACTGCTTAGC | GGCATGGACTGTGGTCATGAG | NM_002046.7 |
| RPL13 | AACAAGTTGAAGTACCTGGCTTTC | TGGTTTTGTGGGGCAGCATA | NM_000977.3 |
| Cyclophilin A | CCCACCGTGTTCTTCGACAT | TTTCTGCTGTCTTTGGGACCT T | NM_021130.4 |
Figure 1mRNA expression in PBMC of lean, obese, T2DM, and T2DM on Metformin of (A) hNAA40; (B) NAMPT; and (C) SIRT-1. Results are presented as Mean ± S.E.M. *P<0.05 vs lean subjects; δP<0.05 vs obese; σP<0.05 vs T2DM.
Demographic Data of the Subjects Participated in the Study. Results are Presented as Mean ± S.E.M
| Caloric Intake | Gender | Age (Years) | BMI kg/m2 | Glucose-0hr (mmol/L) | Glucose-1hr (mmol/L) | Glucose-2hr (mmol/L) | Glucose-3hr (mmol/L) | Insulin-0hr (µU/mL) | Insulin-1hr (µU/mL) | Insulin-2hr (µU/mL) | Insulin-3hr (µU/mL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose | 11M, 1F | 21.6 ± 0.29 | 21.5 ± 0.59 | 4.9 ± 0.11 | 5.1 ± 0.47 | 4.3 ± 0.95* | 3.9 ± 0.23* | 5.7 ± 0.73 | 36.1 ± 6.62* | 27.7 ± 7.83* | 8.2 ± 3.22 |
| Lipids | 12M | 21.3 ± 0.23 | 22.0 ± 0.46 | 4.9 ± 0.1 | 4.6 ± 0.11 | 4.5 ± 0.10* | 4.6 ± 0.10* | 7.5 ± 1.12 | 9.3 ± 1.61 | 7.4 ± 1.34 | 4.8 ± 0.89 |
| Whey Proteins | 12M | 21.4 ± 0.40 | 22.4 ± 0.59 | 4.9 ± 0.15 | 4.1 ± 0.13* | 4.4 ± 0.13* | 4.4 ± 0.12* | 8.1 ± 0.83 | 28.7 ± 3.76* | 22.9 ± 2.87* | 18.3 ± 2.31* |
| Water | 35M, 1F | 21.4 ± 0.18 | 22.0 ± 0.55 | 4.9 ± 0.06 | 4.9 ± 0.18 | 4.8 ± 0.10 | 4.8 ± 0.10 | 5.6 ± 0.39 | 5.4 ± 0.54 | 5.6 ± 0.56 | 5.6 ± 0.71 |
Note: *P<0.05 vs baseline value (0 hr post-caloric challenge).
Figure 2hNAA40, NAMPT, and SIRT-1 mRNA expression levels in PBMC following (A) glucose; (B), Whey proteins; and (C) lipids at 0, 1, 2, and 3 hrs post-caloric challenge. Results are presented as Mean ± S.E.M. *P<0.05 vs water intake; n=12 per group.
Figure 3A proposed mechanism by which Metformin could be exerting its anti-aging properties. Insulin resistance and chronic food intake may lead to an increased inflammatory state present in T2DM which results in an increase in hNAA40 and reduction in NAMPT and SIRT-1. Metformin could be exerting its effect by reducing caloric intake, insulin resistance, and inflammation.